Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + ipilimumab + nivolumab + pegylated liposomal doxorubicin
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of four components: cyclophosphamide (an alkylating agent), ipilimumab (a CTLA-4 inhibitor), nivolumab (a PD-1 inhibitor), and pegylated liposomal doxorubicin (an anthracycline chemotherapy agent). The pegylated liposomal doxorubicin component is enclosed in pegylated liposomes, which slows down removal of the medicine, allowing it to circulate in the blood for longer and reduces effects on healthy tissues and cells, making it less likely to cause certain side effects compared to standard doxorubicin.
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAPDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + ipilimumab + nivolumab + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + ipilimumab + nivolumab + pegylated liposomal doxorubicin.